» Articles » PMID: 38570732

Sex Steroid Levels in Women With Hypopituitarism: A Case-controlled Observational Study

Overview
Specialty Endocrinology
Date 2024 Apr 3
PMID 38570732
Authors
Affiliations
Soon will be listed here.
Abstract

Context: Women with hypopituitarism remain at increased risk of morbidity and mortality. Insufficient replacement of sex steroids has been suggested as a contributing factor, but sex steroid levels in women with hypopituitarism have not been comprehensively mapped.

Objective: To quantify sex steroids in women with hypopituitarism by a high-sensitivity assay.

Methods: Using a combination of clinical and biochemical criteria, women with hypopituitarism (n = 104) who started GH replacement in 1995 to 2014 at a single center were categorized as eugonadal or having hypogonadotropic hypogonadism (HH). A population-based cohort of women (n = 288) served as controls. Eugonadal women and controls were categorized as pre-/postmenopausal and HH women as younger/older (≤ or >52 years). Dehydroepiandrosterone (DHEA), androstenedione, testosterone, dihydrotestosterone, progesterone, 17αOH-progesterone, estradiol, and estrone were analyzed by a validated liquid chromatography-tandem mass spectrometry assay.

Results: Among both premenopausal/younger and postmenopausal/older women, women with HH had lower levels of sex steroid precursors (DHEA, androstenedione) and androgens (testosterone and dihydrotestosterone) than controls. Progesterone, 17αOH-progesterone, estrone, and estradiol showed similar patterns. Women with HH and ACTH deficiency had markedly lower concentrations of all sex hormones than those without ACTH deficiency.

Conclusion: This study demonstrates for the first time a broad and severe sex steroid deficiency in both younger and older women with HH, particularly in those with combined gonadotropin and ACTH deficiency. The health impact of low sex steroid levels in women with hypopituitarism requires further study, and women with combined gonadotropin and ACTH deficiency should be a prioritized group for intervention studies with sex hormone replacement.

References
1.
Higham C, Johannsson G, Shalet S . Hypopituitarism. Lancet. 2016; 388(10058):2403-2415. DOI: 10.1016/S0140-6736(16)30053-8. View

2.
Islam R, Bell R, Handelsman D, McNeil J, Nelson M, Reid C . Associations between blood sex steroid concentrations and risk of major adverse cardiovascular events in healthy older women in Australia: a prospective cohort substudy of the ASPREE trial. Lancet Healthy Longev. 2022; 3(2):e109-e118. PMC: 8896500. DOI: 10.1016/S2666-7568(22)00001-0. View

3.
Palacios S, Henderson V, Siseles N, Tan D, Villaseca P . Age of menopause and impact of climacteric symptoms by geographical region. Climacteric. 2010; 13(5):419-28. DOI: 10.3109/13697137.2010.507886. View

4.
Rivera C, Grossardt B, Rhodes D, Brown Jr R, Roger V, Melton 3rd L . Increased cardiovascular mortality after early bilateral oophorectomy. Menopause. 2008; 16(1):15-23. PMC: 2755630. DOI: 10.1097/gme.0b013e31818888f7. View

5.
Rothman M, Carlson N, Xu M, Wang C, Swerdloff R, Lee P . Reexamination of testosterone, dihydrotestosterone, estradiol and estrone levels across the menstrual cycle and in postmenopausal women measured by liquid chromatography-tandem mass spectrometry. Steroids. 2010; 76(1-2):177-82. PMC: 3005029. DOI: 10.1016/j.steroids.2010.10.010. View